Novo and Lilly Reduce Prices of Weight-Loss Drugs in China
Novo Nordisk and Eli Lilly have taken a major step in China’s healthcare market by cutting prices of their leading weight-loss drugs, a move that could expand access for millions of patients and reshape competition in the pharmaceutical sector. Novo and Lilly reduced prices as China faces rising obesity rates, stronger local competition, and upcoming patent expiries for key medicines.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
